NovoCure (NVCR) released Loss for fourth quarter of -$24.499 million
The company's bottom line totaled -$24.499 million, or -$0.22 per share. This compares with -$65.922 million, or -$0.61 per share, last year.
The company's revenue for the period rose 8.1% to $174.350 million from $161.266 million last year.
NovoCure earnings at a glance (GAAP) :
-Earnings: -$24.499 Mln. vs. -$65.922 Mln. last year.-EPS: -$0.22 vs. -$0.61 last year.-Revenue: $174.350 Mln vs. $161.266 Mln last year.
This rise in fourth-quarter revenue reflects an increase in active patients on therapy.
Looking ahead, for the full year, NovoCure anticipates a rise in revenue.
For fiscal 2026, the company expects adjusted EBITDA of negative $20 million to $0 million, with revenue of $675 million to $705 million.
For fiscal 2025, NovoCure has posted adjusted EBITDA of negative $34.318 million, with revenue of $655.353 million.
NVCR was down by 7.27% at $13.90 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.